Clinical trial
A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.
NCT02506140 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.
- Lead sponsor
- Beijing Tiantan Hospital
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 31, 2015
- Completion date
- March 31, 2018
- Enrollment
- 675 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.